Patents by Inventor Anna Ayre

Anna Ayre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection and use of antiviral resistance mutations
    Patent number: 9932646
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: April 3, 2018
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stehpen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman Leipzig, Thomas Bock Tuebingen, William Sievert, Sharon Lewin
  • Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
    Patent number: 9702005
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: July 11, 2017
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph John Sasadeusz, Peter William Angus, William Sievert
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 9701982
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: July 11, 2017
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Antiviral resistance mutants and applications thereof
    Patent number: 9682109
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: June 20, 2017
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Peter William Angus
  • DETECTION AND USE OF ANTIVIRAL RESISTANCE MUTATIONS
    Publication number: 20160032410
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.
    Type: Application
    Filed: October 14, 2014
    Publication date: February 4, 2016
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman Leipzig, Thomas Bock Tuebingen, William Sievert, Sharon Lewin
  • Detection and use of antiviral resistance mutations
    Patent number: 8859198
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: October 14, 2014
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman, Thomas Bock, William Sievert, Sharon Lewin
  • HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF
    Publication number: 20140296504
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: November 26, 2013
    Publication date: October 2, 2014
    Applicant: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF
    Publication number: 20140199268
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: February 5, 2013
    Publication date: July 17, 2014
    Applicant: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
    Patent number: 8592143
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: November 26, 2013
    Assignee: ABL SA
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Danielle Colledge, Joseph Sasadeusz, Peter William Angus, William Sievert
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 8367317
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: February 5, 2013
    Assignee: Melbourne Health; St. Vincent's Hospital Melbourne; Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Logarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Viral variants
    Patent number: 8273527
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: September 25, 2012
    Assignee: Melbourne Health
    Inventors: Angeline Bartholomeusz, Margaret Littlejohn, Anna Ayres, Stephen Locarnini
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 8211443
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: July 3, 2012
    Assignees: Melbourne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Viral variants with altered susceptibility to nucleoside analogs and uses thereof
    Patent number: 8211633
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: July 3, 2012
    Assignees: Melbourne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
  • VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF
    Publication number: 20110236422
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: December 23, 2010
    Publication date: September 29, 2011
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Logarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • Viral variants detection and application
    Patent number: 8008000
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: August 30, 2011
    Assignees: Melbourne Health, Austin Health, Southern Health, Alfred Health, St. Vincent's Hospital Melbourne
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Lilly Ka Wai Yuen, Joseph John Sasadeusz
  • VIRAL VARIANTS WITH ALTERED SUSCEPTABILITY TO NUCLOESIDE ANALOGS AND USES THEREOF
    Publication number: 20110189652
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Application
    Filed: July 9, 2010
    Publication date: August 4, 2011
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
  • Viral variants with altered susceptibility to nucleoside analogs and uses thereof
    Patent number: 7989162
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: August 2, 2011
    Assignees: Melbourne Health, Austin Health, Southern Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Peter William Angus, William Sievert
  • Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same
    Patent number: 7931907
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: April 26, 2011
    Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health Service
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
  • Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
    Patent number: 7887813
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 15, 2011
    Assignees: Melbourne Health, St. Vincent's Hospital Melbourne, Austin Health
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
  • HBV variants detection and application
    Patent number: 7875423
    Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: January 25, 2011
    Assignees: Melbourne Health, Austin Health, Southern Health, Alfred Health, St. Vincent's Hospital Melbourne
    Inventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Lilly Ka Wai Yuen, Joseph John Sasadeusz